Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Real estate firm Fathom, which trades publicly on the Nasdaq, is adopting a Bitcoin reserve strategy by buying the ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

The man behind popular AI bot Truth Terminal sold off a huge chunk of Fartcoin holdings, prompting a price plunge for the ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

The San Francisco 49ers had a dreadful season, but there were still some silver linings. Injuries decimated the 49ers' offense throughout the year, helping sink them from Super Bowl participants ...

In a significant industry move, Eli Lilly announced plans to acquire Scorpion Therapeutics' experimental cancer therapy, STX-478, for $2.5 billion. This acquisition aims to bolster Eli Lilly's cancer ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...